Agilent Technologies Inc. (NYSE: A) today launched the Genomic
DNA ScreenTape, a prepackaged consumables device that works with the
company's 2200 TapeStation instrument to determine the quantity, size
and quality of genomic DNA in less than two minutes per sample, using
only one microliter of material.
"The automated 2200 TapeStation and new Agilent Genomic DNA ScreenTape
address an important bottleneck and revolutionize the currently
subjective quality assessment of genomic DNA," said Dr. Donna McDade
Walker, product manager for microfluidics at Agilent. "Within minutes of
testing their genomic DNA samples, researchers can be confident that
their starting materials are of the highest quality. This introduction
demonstrates our commitment to expading the range of automated sample
QC tools for next-generation sequencing and workflows for array
comparative genome hybridization."
The quality of genomic data depends on the quality of the starting
material. Therefore, it is imperative to determine whether samples
contain a sufficient quantity of intact, high-quality genomic DNA before
committing time, money and resources to a genomics experiment. The
standard, manual method for assessing the quality of genomic DNA samples
is laborious, can take several hours to complete and is prone to
For more information about the new Agilent Genomic DNA ScreenTape, visit www.agilent.com/genomics/QCgDNA.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company's 20,500
employees serve customers in more than 100 countries. Agilent had
revenues of $6.9 billion in fiscal 2012. Information about Agilent is
available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
[ Back To NFVZone's Homepage ]